Evotec SE (EVOTF)
EVOTF is quoted over the counter, not listed on an exchange. Evotec SE files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | EVOTF, quoted over the counter |
| SEC CIK | 0001412558 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Hamburg |
| Incorporated in | Germany |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-04-08 |
| Cash and burn | 418.5M EUR cash; operating cash flow -2.3M EUR a quarter. | Report 2025-12-31 |
| Shares outstanding | 355,557,814 (2025-12-31); 355,106,912 a year earlier; 353,905,306 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO AG Wirtschaftsprüfungsgesellschaft, Berlin, Germany | PCAOB Form AP 2026-05-08 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | 788.4M EUR | -103.5M EUR | -9.2M EUR | 418.5M EUR | 276.4M EUR | 788.4M EUR | 20-F 2026-04-08 |
| FY 2024 2024-12-31 | 797.0M EUR | -196.1M EUR | 18.2M EUR | 306.4M EUR | 287.6M EUR | 797.0M EUR | 20-F 2025-04-17 |
| FY 2023 2023-12-31 | 781.4M EUR | -83.9M EUR | 36.4M EUR | 510.9M EUR | 437.1M EUR | 781.4M EUR | 20-F 2025-04-17 |
| FY 2022 2022-12-31 | 751.4M EUR | -175.7M EUR | 205.8M EUR | 415.2M EUR | 329.9M EUR | 751.4M EUR | 20-F 2025-04-17 |
| FY 2021 2021-12-31 | 618.0M EUR | 215.5M EUR | 126.6M EUR | 699.3M EUR | 362.5M EUR | 618.0M EUR | 20-F 2024-08-14 |
| FY 2020 2020-12-31 | 500.9M EUR | 6.3M EUR | 44.7M EUR | 422.6M EUR | 15.4M EUR | 500.9M EUR | 20-F 2023-05-12 |
| FY 2019 2019-12-31 | 446.4M EUR | 38.2M EUR | 42.2M EUR | 277.0M EUR | No debt tags | 446.4M EUR | 20-F 2022-04-26 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2021-11-05 |
| Latest annual report | 20-F | 2026-04-08 |
| Latest quarterly / interim | 6-K | 2026-11-05 |
Source: SEC EDGAR submissions feed, 190 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier